Abstract
The study was conducted at RIMS general Hospital Psychiatry OP and study evaluated comparative efficacy and safety Lurasidone in comparison to Olanzapine in first episode schizophrenia diagnosed based on ICD-10.126 first episode schizophrenia patients participated in the study out which 60 patients were in olanzapine group and 66 patients Lurasidone group. PANSS and CGI-I were used assess and compare efficacy. Lurasidone was non inferior to olanzapine in decreasing PANSS score from baseline to end of study at 12th week (95% CI: -8.9 to 4.5). Lurasidone and Olanzapine were equally effective in treating the first episode schizophrenia.
Conclusion: In our study after analysis Lurasidone was equally efficacious in treating first episode of schizophrenia.
Keywords: Lurasidone, Olanzapine, first episode schizophrenia, response rates, PANSS, CGI-I.
References
- Häfner H, an der Heiden W. Epidemiology of Schizophrenia. The Canadian Journal of Psychiatry. 1997;42:139–151. doi:1177/070674379704200204
- Messias, Erick, Chuan-Yu Chen, and William W Eaton. “Epidemiology of Schizophrenia: Review of Findings and Myths.” The Psychiatric Clinics of North America 30, no. 3 (September 2007): 323–38. https://doi.org/10.1016/j.psc.2007.04.007.
- Jablensky, A., N. Sartorius, G. Ernberg, M. Anker, A. Korten, J. E. Cooper, R. Day, and A. Bertelsen. “Schizophrenia: Manifestations, Incidence and Course in Different Cultures. A World Health Organization Ten-Country Study.” Psychological Medicine. Monograph Supplement 20 (1992): 1–97.
- Kumar, Ajit, Soumitra S. Datta, Stephen D. Wright, Vivek A. Furtado, and Paul S. Russell. “Atypical Antipsychotics for Psychosis in Adolescents.” The Cochrane Database of Systematic Reviews, no. 10 (October 15, 2013): CD009582. https://doi.org/10.1002/14651858.CD009582.pub2.
- Ishibashi, Tadashi, Tomoko Horisawa, Kumiko Tokuda, Takeo Ishiyama, Masaaki Ogasa, Rie Tagashira, Kenji Matsumoto, et al. “Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity.” Journal of Pharmacology and Experimental Therapeutics 334, no. 1 (July 1, 2010): 171. https://doi.org/10.1124/jpet.110.167346
- Rummel-Kluge, Christine, Katja Komossa, Sandra Schwarz, Heike Hunger, Franziska Schmid, Werner Kissling, John M Davis, and Stefan Leucht. “Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-Analysis of Head-to-Head Comparisons.” Schizophrenia Bulletin 38, no. 1 (January 2012): 167–77. https://doi.org/10.1093/schbul/sbq042.
- Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review. PubMed PMID: 20238348; PubMed Central PMCID: PMC4169107.
- Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. (1992): The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis180: 723–728
- National Institute of Mental Health. (1976a): Clinical Global Impression. In Guy W (ed), ECDEU Assessment Manual for Psychopharmacology Revised Edition. Rockville, MD, National Institute of Mental Health, pp 218–222
- Simpson G, Angus JA. (1970): A rating scale for extrapyramidal side effects. Acta Psychiat Scand45(Suppl 212):11–19
- Leucht, Stefan, John M. Kane, Werner Kissling, Johannes Hamann, Eva Etschel, and Rolf R. Engel. “What Does the PANSS Mean?” Schizophrenia Research 79, no. 2–3 (November 15, 2005): 231–38. https://doi.org/10.1016/j.schres.2005.04.008.
- Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, the Olanzapine HGAP Study Group. (1996a): Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology124: 159–167
- Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Review. PubMed PMID: 21129135.
- Amico, K Rivet. “Percent Total Attrition: A Poor Metric for Study Rigor in Hosted Intervention Designs.” American Journal of Public Health 99, no. 9 (September 2009): 1567–75. https:// doi.org/10.2105/AJPH.2008.134767.
- Nakamura, Mitsutaka, Masaaki Ogasa, John Guarino, Debra Phillips, Joseph Severs, Josephine Cucchiaro, and Antony Loebel. “Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial.” The Journal of Clinical Psychiatry 70, no. 6 (June 2009): 829–36. https://doi.org/10.4088/JCP.08m04905.
- Risbood, Vineeta, Jennifer R. Lee, Jennifer Roche-Desilets, and Matthew A. Fuller. “Lurasidone: An Atypical Antipsychotic for Schizophrenia.” The Annals of Pharmacotherapy 46, no. 7–8 (August 2012): 1033–46. https://doi.org/10.1345/aph.1M721.
- Goldman, Robert, Antony Loebel, Josephine Cucchiaro, Ling Deng, and Robert L. Findling. “Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.” Journal of Child and Adolescent Psychopharm-acology 27, no. 6 (August 2017): 516–25. https://doi.org/10.1089/cap.2016.0189.
Corresponding Author
Dr. Kandavalli Sridevi M.D (Pharmacology)
Mobile 73826226669, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i3.124
